SCHEMBL753268

SCHEMBL753268

COC(=O)c1ccc(Oc2ccc([C@@H](C)[C@@](O)(c3ccc(=O)n(C)c3)C(F)(F)F)c(Cl)c2)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.37
NR1H2 P55055 1/20 0.35
NR1H3 Q13133 1/20 0.35
PDK1 Q15118 2/20 0.34
PDK2 Q15119 2/20 0.34
PDK3 Q15120 2/20 0.34
PDK4 Q16654 2/20 0.34
NPBWR1 P48145 1/20 0.34
ALDH1A1 P00352 1/20 0.33
PTGER4 P35408 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
SCN9A Q15858 1/20 0.32
POLB P06746 1/20 0.32
MAPT P10636 1/20 0.32
KDR P35968 1/20 0.32
MMP2 P08253 1/20 0.32
MMP9 P14780 1/20 0.32
P2RX3 P56373 1/20 0.32
MDM4 O15151 1/20 0.32
MDM2 Q00987 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL480948 1.00 LMNA (0.37) LMNANR1H2NR1H3PDK1PDK2
SCHEMBL753038 0.92 PTGER4 (0.38) NR1H2NR1H3ALDH1A1PTGER4POLB
SCHEMBL734434 0.92 PTGER4 (0.38) NR1H2NR1H3ALDH1A1PTGER4POLB
SCHEMBL753039 0.91 SCN8A (0.34) LMNAPDK1PDK2PDK3PDK4
SCHEMBL480093 0.91 SCN8A (0.34) LMNAPDK1PDK2PDK3PDK4
SCHEMBL480403 0.87 LMNA (0.36) LMNANR1H2NR1H3NPBWR1ALDH1A1
SCHEMBL753341 0.87 LMNA (0.36) LMNANR1H2NR1H3NPBWR1ALDH1A1
SCHEMBL480502 0.86 BRD4 (0.37) ALDH1A1NR3C1
SCHEMBL734909 0.85 S1PR2 (0.34) PTGER4NR3C1
SCHEMBL754450 0.85 S1PR2 (0.34) PTGER4NR3C1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138189-B2 Substituted benzene compounds as modulators of the glucocorticoid receptor HOFFMAN-LA ROCHE INC. (US) 2012-03-20 US disclosed
US-8138189-B2 Substituted benzene compounds as modulators of the glucocorticoid receptor HOFFMAN-LA ROCHE INC. (US) 2012-03-20 US disclosed
US-20100249139-A1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS HOFFMANN-LA ROCHE, INC. 2010-09-30 US disclosed
US-20100249139-A1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS HOFFMANN-LA ROCHE, INC. 2010-09-30 US disclosed
WO-2010108902-A1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2010-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249139-A1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS NR3C1, NR3C2, CRHR1 LMNA 1995/4885NR1H2 89/4885NR1H3 113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.